Price Alert

Adamas Pharmaceuticals In... (ADMS)

NASDAQ: ADMS · Real-Time Price · USD

8.22

0.00 (0.00%)

At close: Apr 24, 2025, 3:47 PM

Adamas Pharmaceuticals Statistics

Share Statistics

Adamas Pharmaceuticals has 0 shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Institutions (%)	n/a
Shares Floating	n/a
Failed to Deliver (FTD) Shares	n/a
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 477.29K, so 0% of the outstanding shares have been sold short.

Short Interest	477.29K
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1

Valuation Ratios

The PE ratio is -2.65 and the forward PE ratio is null. Adamas Pharmaceuticals's PEG ratio is 0.05.

PE Ratio	-2.65
Forward PE	n/a
PS Ratio	2.05
Forward PS	n/a
PB Ratio	-3.05
P/FCF Ratio	-3
PEG Ratio	0.05

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Adamas Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.2, with a Debt / Equity ratio of -2.6.

Current Ratio	3.2
Quick Ratio	3
Debt / Equity	-2.6
Debt / EBITDA	-3
Debt / FCF	-2.56
Interest Coverage	-3.34

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$539.57K
Profits Per Employee	$-415.96K
Employee Count	138
Asset Turnover	0.62
Inventory Turnover	0.28

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is 2.82, so Adamas Pharmaceuticals's price volatility has been higher than the market average.

Beta	2.82
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	1,338,689

Income Statement

In the last 12 months, Adamas Pharmaceuticals had revenue of 74.46M and earned -57.4M in profits. Earnings per share was -1.63.

Revenue	74.46M
Gross Profit	72.42M
Operating Income	-44.16M
Net Income	-57.4M
EBITDA	-43.31M
EBIT	-44.16M
Earnings Per Share (EPS)	-1.63

Full Income Statement

Balance Sheet

The company has 71.66M in cash and 129.96M in debt, giving a net cash position of -58.3M.

Cash & Cash Equivalents	71.66M
Total Debt	129.96M
Net Cash	-58.3M
Retained Earnings	-505.29M
Total Assets	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -50.71M and capital expenditures 0, giving a free cash flow of -50.71M.

Operating Cash Flow	-50.71M
Capital Expenditures	n/a
Free Cash Flow	-50.71M
FCF Per Share	-1.44

Full Cash Flow Statement

Margins

Gross margin is 97.26%, with operating and profit margins of -59.31% and -77.09%.

Gross Margin	97.26%
Operating Margin	-59.31%
Pretax Margin	-77.09%
Profit Margin	-77.09%
EBITDA Margin	-58.17%
EBIT Margin	-59.31%
FCF Margin	-68.1%

Dividends & Yields

ADMS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for ADMS.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a